A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer

• DOI: 10.18632/oncotarget.7990
• Publication Date: 2016-03-08T13:04:11Z
• Authors: Qian Zhao; Shengqiong Deng; Guangxue Wang; Cuicui Liu; Lingyu Meng; Shanshan Qiao; Lei Shen; Yue Zhang; Jinhui Lü; Wenshu Li; Yuzhen Zhang; Min Wang; Richard G. Pestell; Chunli Liang; Zuoren Yu
• Keywords: Cancer Biomarkers

// Qian Zhao 1, * , Shengqiong Deng Guangxue Wang Cuicui Liu 2 Lingyu Meng Shanshan Qiao 1 Lei Shen Yue Zhang Jinhui Lü 3 Wenshu Li Yuzhen Min 4 Richard G. Pestell Chunli Liang Zuoren Yu 2, Research Center for Translational Medicine, Medical Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Shanghai, China Dalian University, Dalian, Basic Sciences, Wenzhou Wenzhou, Department Cancer Biology, Sidney Kimmel Center, Thomas Jefferson Philadelphia, USA These authors contributed equally to this work Correspondence to: Yu, e-mail: [e-mail] Keywords: circulating miRNA, direct quantification, biomarker, metastatic breast cancer, miR-106a Received: November 29, 2015 Accepted: February 21, 2016 Published: March 08, ABSTRACT Circulating miRNAs are protected from ribonuclease degradation by assembly into microvesicles and exosomes. Releasing completely these particles is the key step quantify miRNAs. Currently purified RNA-based quantitative analysis widely used while it time cost consuming with high risk those low abundance due partial loss RNA during steps total extraction small enrichment. Herein, we optimized a simple, effective time-saving method directly measure plasma without isolation. It based on complete miRNA release protein complexes, followed miRNA-specific reverse transcription real-time PCR amplification. By comparison approach, quantification showed more efficiency analysis, higher accuracy specificity. application clinical samples combined screening upregulation in blood was validated cancer patients, indicating potential biomarker cancer.